# Does Arizona Medicaid (AHCCCS) Cover Ozempic, Wegovy or Zepbound? By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07 Canonical page: https://glpwatchdog.org/research/arizona-ahcccs-glp1-coverage > Arizona's Medicaid program excludes weight-loss drugs and refuses Zepbound for sleep apnea. Ozempic became a non-preferred diabetes drug behind Mounjaro on October 1, 2026, and Wegovy is approved only for heart-risk reduction at 45 and up or for MASH. ## Key points - Since October 1, 2026, Mounjaro, Trulicity and Victoza are the preferred diabetes GLP-1s in fee-for-service; Ozempic needs failed trials of all three. - Weight-loss drugs are excluded, and the criteria name Zepbound for sleep apnea as a plan exclusion. - Wegovy for heart risk needs age 45 or older, a BMI of 30 or more, a listed heart history and no diabetes, six months at a time. - Wegovy for MASH needs F2 or F3 fibrosis on a named test and a liver, digestive or hormone specialist. - Health plan members appeal to the plan within 60 days of the notice, then may ask for a state fair hearing. Arizona Medicaid, called AHCCCS, covers Ozempic only for type 2 diabetes, and in its fee-for-service program Ozempic is a non-preferred drug that needs failed 90-day trials of Trulicity, Victoza or generic liraglutide, and Mounjaro first.[1] As of November 2026 no GLP-1 is covered for weight loss, Zepbound for sleep apnea is refused as a plan exclusion, and Wegovy is approved only for heart-risk reduction or the liver disease MASH.[1][2][4] > **About this article.** This page reads the OptumRx criteria AHCCCS posts for its fee-for-service members (effective November 1, 2026), the AHCCCS drug list and the fee-for-service billing manual, as of November 7, 2026. Most AHCCCS members are in a health plan with its own pharmacy manager, and plan criteria may be worded differently. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Does AHCCCS cover Ozempic? Yes, for type 2 diabetes, which is the use on its label.[9] What surprises many people is the order. Since October 1, 2026 the preferred GLP-1s in fee-for-service are Mounjaro, Trulicity, brand Victoza and generic liraglutide; Ozempic and exenatide are non-preferred.[1][14] The change log for that date reads “Mounjaro to PDL, Exenatide to NPD.”[14] A November 1, 2026 revision kept that order and tightened the paperwork: the A1C lab report must now be submitted, the 90-day metformin trial must show up in paid pharmacy claims, and the request must confirm the drug will not be taken with another GLP-1.[1] *AHCCCS fee-for-service GLP-1 criteria for type 2 diabetes, guideline effective November 1, 2026* | Drug | Status | What the request needs | Approval | | --- | --- | --- | --- | | Mounjaro, Trulicity, Victoza, generic liraglutide | Preferred, PA required | Type 2 diabetes with a baseline A1C of 6.5% or more (lab report required); 90 days of metformin at 1,500 mg a day or more shown in paid claims, or a reason it cannot be used; age 10 or older; not for weight loss; no second GLP-1 | 12 months | | Ozempic injection, exenatide | Non-preferred | Everything above, plus failed 90-day trials of Trulicity, Victoza or liraglutide, and Mounjaro; age 18 or older | 12 months | | Ozempic tablets, Rybelsus | Non-preferred | Everything above for Ozempic, or an inability to inject plus failed trials of four SGLT2 drugs; age 18 or older | 12 months | Two practical points follow. Mounjaro and Zepbound contain the same medicine, tirzepatide, so a person with diabetes is better placed asking for Mounjaro, now a preferred drug, than for Ozempic.[10] And the pill route has its own door for people who cannot inject because of a physical or visual impairment, skin changes at injection sites or a documented needle phobia.[1] The AHCCCS drug list has no semaglutide row at all, and its header says drugs left off the list may still be available through prior authorization.[3] ## Does AHCCCS cover Wegovy or Zepbound for weight loss? No. The fee-for-service billing manual lists “medications used for weight loss treatment” among its pharmacy exclusions, and the Wegovy criteria tell reviewers to deny a weight-loss request “as a benefit exclusion.”[4][2] The diabetes criteria add the same test for every GLP-1: the drug must not be used for weight loss.[1] Under federal law, a state may leave weight-loss drugs out of Medicaid, and our explainer on [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers that choice.[8] The exclusion is written broadly. Unlike states that treat sleep apnea as a separate medical use, Arizona’s criteria tell reviewers to deny drugs that “improve conditions caused by obesity,” with Zepbound for sleep apnea as the named example.[1] The FDA approved Zepbound for moderate to severe sleep apnea in adults with obesity, so the refusal reflects Arizona’s benefit design rather than any doubt about the drug.[10] See [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) for the trial data. ## Will AHCCCS cover Wegovy for heart disease? Yes, with prior authorization, but the test is stricter than the label in three ways.[2][11] The patient must be 45 or older, the BMI must be 30 or more, and the heart history must come from a short list: a prior heart attack, or a code for an old heart attack, cardiac arrest, a pacemaker, bypass surgery, a replaced heart valve or a coronary stent or graft.[2] A past stroke or peripheral artery disease on its own is not on that list, even though the label’s heart use covers adults with established cardiovascular disease more generally.[2][11] - **After a heart attack:** records or claims showing the patient takes a cholesterol drug, a beta blocker, an ACE inhibitor or ARB or ARNI, and an antiplatelet drug, or cannot take any of them.[2] - **Exclusions:** diabetes or an A1C of 6.5% or more, class IV heart failure, or end-stage kidney disease.[2] - **Approval length:** six months at a time, and each renewal again needs a BMI of 30 or more.[2] The diabetes exclusion means someone with diabetes and heart disease goes through the diabetes criteria instead, where the preferred drugs come first.[1][2] ## Does AHCCCS cover Wegovy for fatty liver disease (MASH)? Yes, since a January 28, 2026 revision added the use.[2] The request covers the Wegovy injection for adults with MASH and fibrosis at stage F2 or F3, with no cirrhosis.[2] The stage must be confirmed by one of the named tests: an ELF blood test, FibroScan or another vibration-controlled liver stiffness scan, the FAST or MAST scores, MRI elastography combined with a FIB-4 score, or a liver biopsy within the past 12 months.[2] A gastroenterologist, hepatologist or endocrinologist must prescribe or consult, and the drug cannot be combined with another GLP-1 or with Rezdiffra.[2] The first approval lasts six months; renewals run 12 months and need evidence the liver is responding, such as better liver tests or imaging.[2] The label approval for MASH is an accelerated one, and our page on [GLP-1s and MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) explains what that means.[11] ## Do AHCCCS health plans follow the same rules? Not necessarily word for word. AHCCCS lists separate pharmacy managers by plan: OptumRx for fee-for-service and UnitedHealthcare Community Plan, Express Scripts for Banner University Family Care, Arizona Complete Health and Care1st, and CVS Caremark for Mercy Care, Health Choice Arizona and Molina.[5] Each plan applies its own prior authorization forms, so call the number on your member card and ask for the plan’s Wegovy or GLP-1 criteria before filing. Our guide to [why Medicaid plans and fee-for-service differ](https://glpwatchdog.org/research/medicaid-managed-care-and-glp1s) explains the split. For fee-for-service members, prescribers fax the OptumRx prior authorization form to 866-463-4838; the OptumRx help desk is (855) 577-6310.[4] ## How do you appeal an AHCCCS denial? Health plan members file the first appeal with the plan, orally or in writing, within 60 days of the notice.[6] If the plan’s answer goes against you, federal rules give at least 90 and at most 120 days from that decision to ask for a state fair hearing, so use the deadline printed on the plan’s notice.[7] An appeal has the most room when the dispute is about evidence: a missing fibrosis test, chart notes for a prior heart attack, or proof of the earlier diabetes drugs. It has little to work with for weight loss or sleep apnea, which the criteria exclude by design.[1][4] Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to send, and the [Arizona state page](https://glpwatchdog.org/states/arizona) collects the Medicaid facts in brief. ## What are the options if AHCCCS will not pay? Cash is the main one, since Lilly’s savings card terms exclude anyone enrolled in Medicaid.[12] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses through Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound.[12][13] Read each offer’s rules on government coverage first. Our list of the [cheapest GLP-1 routes without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares them. ## Frequently asked questions ### Does Arizona Medicaid cover Ozempic? Yes, for type 2 diabetes with prior authorization. In AHCCCS fee-for-service, Ozempic has been non-preferred since October 1, 2026, so the request needs failed 90-day trials of Trulicity, Victoza or generic liraglutide, and Mounjaro, along with metformin shown in paid claims and an A1C lab result of 6.5% or more. It is not covered for weight loss. ### Does AHCCCS cover Wegovy? Not for weight loss. As of November 2026 Wegovy can be approved for heart-risk reduction at age 45 or older with a BMI of 30 or more, a qualifying heart history and no diabetes, or as an injection for MASH with F2 or F3 fibrosis confirmed by a named test and a liver or hormone specialist involved. ### Does AHCCCS cover Zepbound for sleep apnea? No. The criteria tell reviewers to deny drugs used to improve conditions caused by obesity, naming Zepbound for sleep apnea, as a plan exclusion. Mounjaro, the same medicine, is covered for type 2 diabetes. ### Is Mounjaro covered by Arizona Medicaid? Yes, for type 2 diabetes. Mounjaro became a preferred GLP-1 in AHCCCS fee-for-service on October 1, 2026. It still needs prior authorization, with a baseline A1C of 6.5% or more and 90 days of metformin or a reason metformin cannot be used. ### How long do I have to appeal an AHCCCS plan denial? Arizona's rule gives 60 days after the date of the notice to appeal to your health plan, orally or in writing. After the plan decides, federal rules allow between 90 and 120 days to request a state fair hearing, and the plan's notice gives the exact date. ## References 1. OptumRx for the Arizona Health Care Cost Containment System (AHCCCS) Prior Authorization Guideline GL-749236: GLP-1 Agonists - AZM, effective November 1, 2026 (revised October 28, 2026). azahcccs.gov. 2026. https://www.azahcccs.gov/Resources/Downloads/PharmacyUpdates/2026/AZMFileseff110126AllGuidelines.pdf 2. OptumRx for the Arizona Health Care Cost Containment System (AHCCCS) Prior Authorization Guideline GL-509188: Wegovy (semaglutide), effective February 1, 2026 (revised January 28, 2026). azahcccs.gov. 2026. https://www.azahcccs.gov/Resources/Downloads/PharmacyUpdates/2026/AZMFileseff110126AllGuidelines.pdf 3. Arizona Health Care Cost Containment System AHCCCS Acute and Long Term Care Drug List, effective November 1, 2026. azahcccs.gov. 2026. https://www.azahcccs.gov/Resources/Downloads/PharmacyUpdates/2026/AHCCCSDrugListEffective2026-11-01.pdf 4. Arizona Health Care Cost Containment System Fee-For-Service Provider Billing Manual, Chapter 12: Pharmacy Services. azahcccs.gov. 2024. https://azahcccs.gov/PlansProviders/Downloads/FFSProviderManual/FFS_Chap12Pharmacy.pdf 5. Arizona Health Care Cost Containment System AHCCCS Pharmacy Claims Processing BINs, PCNs and Group Numbers (2026). azahcccs.gov. 2026. https://www.azahcccs.gov/PlansProviders/Downloads/PharmacyUpdates/2026_PharmacyClaimsProcessing_BINs.pdf 6. State of Arizona Ariz. Admin. Code R9-34-209: Enrollee Time-frame for Filing an Appeal or Grievance with the Contractor. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/arizona/Ariz-Admin-Code-SS-R9-34-209 7. Code of Federal Regulations 42 CFR 438.408: Resolution and notification: Grievances and appeals. eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-438/subpart-F/section-438.408 8. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 9. Novo Nordisk OZEMPIC (semaglutide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 10. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 11. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 12. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 13. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html 14. OptumRx for the Arizona Health Care Cost Containment System (AHCCCS) Prior Authorization Guideline GL-715192: GLP-1 Agonists - AZM, effective October 1, 2026 (revised September 11, 2026). azahcccs.gov. 2026. https://www.azahcccs.gov/Resources/Downloads/PharmacyUpdates/2026/AZMFileseff100126AllGuidelines.pdf --- Cite as: GLP Watchdog, Nora Bissett, "Does Arizona Medicaid (AHCCCS) Cover Ozempic, Wegovy or Zepbound?", published 2026-11-07. https://glpwatchdog.org/research/arizona-ahcccs-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/arizona-ahcccs-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.